Login to Your Account



Imetelstat Implodes in Breast Cancer Trial, Geron Swoons

By Marie Powers
Staff Writer

Tuesday, September 11, 2012
The melancholy on the Geron Corp. conference call early Monday morning was palpable after the company disclosed its decision to halt the Phase II study of imetelstat in metastatic HER2-negative breast cancer after an unplanned interim analysis revealed a greater number of deaths in the treatment arm than the comparator arm.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription